ONAMI-supported technology gains $600M to advance immunotherapy

June 15th, 2018

"....TomagaVax had raised $10 million in grants over the first six years of its existence. Vir’s pockets are considerably deeper, with $600 million at its disposal. As an investor, the Gates Foundation is funding clinical development of the Picker team’s vaccine vectors, which could protect millions of people against HIV, tuberculosis, malaria, hepatitis B and more. The first human clinical trial, for the HIV vaccine, is expected to kick off in one year."

See the full Portland Business Journal story (subscription required) here

Tomegavax/Vir's technology was developed at the Vaccine and Gene Therapy Institute on OHSU's west campus